Praxis Precision Medicines, Inc. - 8-K Filing

Praxis Precision Medicines reports Q3 2026 net loss of $94.2 million and announces cash runway into 2028 with $1.3 billion in liquidity. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PRAX

Read the full article at SEC EDGAR

Part of the story AXT INC - 8-K Filing (11 articles)

More Regulatory news